Silversmith Partners I GP LLC Has $39.22 Million Position in LifeStance Health Group, Inc. $LFST

Silversmith Partners I GP LLC lowered its position in LifeStance Health Group, Inc. (NASDAQ:LFST) by 57.0% in the 1st quarter, HoldingsChannel reports. The fund owned 6,157,127 shares of the company’s stock after selling 8,167,070 shares during the period. LifeStance Health Group accounts for about 100.0% of Silversmith Partners I GP LLC’s holdings, making the stock its biggest position. Silversmith Partners I GP LLC’s holdings in LifeStance Health Group were worth $39,221,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in LifeStance Health Group by 21.1% in the 4th quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock valued at $124,608,000 after acquiring an additional 3,086,506 shares during the period. Jennison Associates LLC increased its stake in shares of LifeStance Health Group by 38.5% in the first quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock worth $65,157,000 after purchasing an additional 2,843,388 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of LifeStance Health Group by 62.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock valued at $26,363,000 after purchasing an additional 1,839,465 shares during the period. Dimensional Fund Advisors LP raised its position in shares of LifeStance Health Group by 27.2% in the third quarter. Dimensional Fund Advisors LP now owns 8,363,607 shares of the company’s stock valued at $45,998,000 after purchasing an additional 1,790,694 shares during the period. Finally, Integral Health Asset Management LLC lifted its stake in shares of LifeStance Health Group by 100.0% during the 4th quarter. Integral Health Asset Management LLC now owns 3,000,000 shares of the company’s stock valued at $21,120,000 after buying an additional 1,500,000 shares in the last quarter. 85.50% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently commented on LFST. BTIG Research raised their price objective on shares of LifeStance Health Group from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Canaccord Genuity Group boosted their target price on shares of LifeStance Health Group from $11.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday. Barclays boosted their target price on shares of LifeStance Health Group from $9.00 to $13.00 and gave the company an “overweight” rating in a report on Tuesday, July 14th. JPMorgan Chase & Co. increased their target price on LifeStance Health Group from $8.00 to $9.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. Finally, KeyCorp raised their price target on LifeStance Health Group from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, LifeStance Health Group has an average rating of “Moderate Buy” and an average target price of $11.12.

Insider Buying and Selling

In other LifeStance Health Group news, Director Darren M. Black sold 5,899,661 shares of the firm’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $8.02, for a total value of $47,315,281.22. Following the completion of the transaction, the director directly owned 23,310,115 shares of the company’s stock, valued at $186,947,122.30. This trade represents a 20.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Eric Shuey sold 243,362 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $8.02, for a total transaction of $1,951,763.24. Following the transaction, the director owned 867,562 shares of the company’s stock, valued at $6,957,847.24. This trade represents a 21.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 7,749,541 shares of company stock valued at $64,017,837. Company insiders own 3.50% of the company’s stock.

LifeStance Health Group Trading Down 3.8%

Shares of LFST opened at $11.01 on Thursday. LifeStance Health Group, Inc. has a twelve month low of $3.74 and a twelve month high of $11.76. The stock has a market cap of $4.27 billion, a PE ratio of 183.50 and a beta of 1.12. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.18. The business’s 50-day moving average price is $9.21 and its 200-day moving average price is $7.77.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. LifeStance Health Group had a net margin of 1.55% and a return on equity of 1.56%. The company had revenue of $403.48 million during the quarter, compared to analyst estimates of $387.46 million. The firm’s revenue for the quarter was up 21.2% compared to the same quarter last year. On average, equities analysts forecast that LifeStance Health Group, Inc. will post 0.12 EPS for the current fiscal year.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.